CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 29 enrolled
Drug / intervention
Ruxolitinib phosphate cream +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00820950
NCT00820950Phase 2Completed
CompareCT.gov

A Double-Blind, Vehicle-Controlled, Rising Dose, Safety, Tolerability, Pharmacokinetic and Preliminary Efficacy Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis

Incyte Corporation·interventional·Posted Jan 12, 2009·Updated Feb 8, 2022

In Brief

A Phase 2 clinical trial evaluating Ruxolitinib phosphate cream, Dovonex® calcipotriene 0.005%, and 2 other interventions for Psoriasis. Completed, enrolled 29 participants across 6 sites.

Detailed Summary

The study is comprised of two parts. The first portion of this study will be a double-blind, Sponsor-unblinded, vehicle-controlled study with application of ruxolitinib or vehicle to paired lesions at least 15 cm apart in patients with active but stable plaque psoriasis. Part 2 of the study is a double-blind, sponsor unblinded, comparison of ruxolitinib with two FDA approved products in patients with active but stable plaque psoriasis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 12, 2009
Enrollment StartMay 31, 2007
Primary CompletionJan 31, 2009
Study CompletionApr 30, 2009
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 17.5 years ago

Interventions

Ruxolitinib phosphate creamdrug

Ruxolitinib phosphate cream 0.5%

Dovonex® calcipotriene 0.005%drug

Cream applied once or twice daily for up to 56 days.

Diprolene® AF betamethasone dipropionate 0.05% cream.drug

Cream applied once or twice daily for up to 56 days

Placebo creamdrug

Cream applied once or twice daily for 56 days

Ruxolitinib phosphate creamdrug

Ruxolitinib phosphate cream 1.0%

Ruxolitinib phosphate creamdrug

Ruxolitinib phosphate cream 1.5%